What Syndex Bio does

Syndex Bio is a Cambridge, UK-based biotechnology company founded in 2022 that has developed mcPCR (methyl-copying PCR), a proprietary platform technology designed to preserve 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification. Conventional PCR cannot copy epigenetic methylation marks; mcPCR uses proprietary methyl transferase enzymes to copy both the four-base genetic code and methylation modifications on newly synthesised strands, enabling analysis from limiting clinical samples including liquid biopsies. The platform supports both whole-genome and targeted workflows with a non-destructive process intended to integrate into downstream genomic and multi-omic analyses. Target applications include oncology testing and early cancer detection, residual disease and treatment monitoring, drug development and patient stratification, and chronic disease detection.

The company operates a B2B go-to-market targeting clinical laboratories, healthcare providers, and research institutions. Revenue is expected to come from one-time licences of the mcPCR platform and reagents, supplemented by professional services tied to clinical workflow development. The company has 17 employees, no disclosed paying customers, and publicly undisclosed pricing. Its founding team includes individuals credited with inventing and commercialising next-generation sequencing (NGS) technology.

In February 2026 Syndex Bio publicly launched the mcPCR platform at the AGBT General Meeting in Orlando and concurrently closed a $15.5 million oversubscribed seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind. Concurrent with the financing, the company formed a board of directors that includes Gautam Kollu, former Chief Commercial Officer of Grail, signalling intent to build an enterprise commercial motion in molecular diagnostics. Syndex Bio is collaborating with undisclosed research groups to advance liquid biopsy applications and plans to compete alongside rivals such as Epinoma in early-stage cancer detection.

Name

Syndex Bio

Legal name

Syndex Bio Limited

Website

https://syndex.bio

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Syndex Bio is a Cambridge, UK biotech startup developing mcPCR, a proprietary PCR-based platform that preserves DNA methylation patterns during amplification, targeting clinical laboratories and research institutions for applications in early cancer detection, liquid biopsy, and disease monitoring.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• DNA methylation analysis
• Molecular diagnostics
• PCR technology platform
• Liquid biopsy reagents
• Epigenetics research tools

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. mcPCR platform and reagents: Revenue expected from selling mcPCR technology, reagents, and kits to clinical laboratories, healthcare providers, and research institutions for DNA methylation analysis applications including early cancer detection, disease monitoring, and clinical diagnostics.
2. Clinical workflow development: Developing clinical workflows and applications that will enable deployment of mcPCR technology in healthcare settings for oncology testing, residual disease monitoring, drug development, and chronic disease detection.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Syndex Bio develops and sells the proprietary mcPCR (methyl-copying PCR) platform, a biotechnology that preserves 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification. The platform enables high-fidelity copying of both epigenetic modifications and the underlying four-base genetic code, overcoming a fundamental 40-year limitation of conventional PCR. The company sells the technology along with reagents and kits to clinical laboratories, healthcare providers, and research institutions for applications including oncology testing, early cancer detection, residual disease monitoring, drug development, patient stratification, and chronic disease detection.

Product overview

Syndex Bio offers a single unified product platform: the mcPCR™ (methyl-copying PCR) platform. This proprietary technology is designed to preserve DNA methylation (5mC) patterns during DNA amplification, addressing a fundamental limitation of conventional PCR where epigenetic information is lost. The platform enables high-fidelity copying of both the methylation patterns and the four-base genetic code, supporting clinical applications in oncology testing, early cancer detection, residual disease monitoring, drug development, patient stratification, and chronic disease detection. The technology supports both whole genome and targeted workflows, enabling genome-wide discovery and targeted follow-up studies.

Differentiator

Problem solved

Functional benefit

Products and services

• mcPCR™ (methyl-copying PCR) Platform A proprietary molecular biology platform technology that preserves 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification using proprietary methyl transferase enzymes. Copies both epigenetic modifications and the underlying four-base genetic code, enabling high-fidelity methylation analysis from limiting clinical samples including liquid biopsies. Sold to clinical laboratories, healthcare providers, and research institutions for DNA methylation-based diagnostics and research applications.

Quantifiable outcome

• Earlier disease detection through sensitive methylation analysis from liquid biopsies
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Undisclosed research groupsminorStrategic or Co-development Partner · 23 February 2026Syndex Bio is collaborating with undisclosed research groups to advance the mcPCR technology for liquid biopsy applications.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Qiagen: Qiagen offers sample-prep, PCR, and methylation-biomarker products (e.g., PyroMark for DNA methylation analysis). Comparable as an established supplier of methylation-analysis tools to clinical and research labs that could partner with, distribute, or compete with Syndex.
• Natera: Natera offers Signatera (tumor-informed MRD) and a methylation-based colorectal screening assay. Comparable in pursuing methylation-aware clinical diagnostics for oncology; serves overlapping biopharma and clinical-lab customers.
• Illumina: Illumina is the dominant NGS platform vendor and now owns GRAIL, giving it both the sequencing infrastructure and methylation-diagnostics portfolio relevant to Syndex's downstream workflows. Comparable as the platform/ecosystem incumbent Syndex's enzyme technology would plug into.
• GRAIL (Illumina): GRAIL pioneered methylation-based multi-cancer early detection (Galleri) and is the most-cited competitor in Syndex's own market landscape. Comparable as a methylation-driven liquid biopsy developer; GRAIL operates at vastly larger scale and is now owned by Illumina.
• Guardant Health: Guardant is a leading liquid biopsy company with methylation-enabled products (e.g., Guardant Infinity, Reveal MRD). Directly comparable target market (oncology, MRD, drug development) and shared reliance on blood-based cfDNA workflows.
• Thermo Fisher Scientific: Thermo Fisher supplies PCR/qPCR instruments, methylation reagents, and clinical diagnostic platforms (e.g., Ion Torrent). Comparable as a broad life-science tools incumbent that could partner with or compete against Syndex for clinical-lab workflows.
• Exact Sciences: Exact Sciences' Cologuard is the canonical commercial methylation-based diagnostic and demonstrates the clinical and commercial viability of methylation biomarkers in screening. Comparable in target customer (clinical labs, payors) and disease focus (early detection).

Emerging players

• Epinoma: Epinoma is explicitly named in Syndex's own source data as a rival competing in early-stage liquid biopsy cancer detection. Comparable as a similarly early-stage, epigenetics-focused liquid biopsy developer pursuing the same beachhead market.
• Singlera Genomics: Singlera develops methylation-based liquid biopsy assays for early cancer detection (e.g., ColonES). Comparable as a methylation-driven diagnostics developer targeting similar clinical applications and customer segments.
• Bluestar Genomics (Genentech): Bluestar developed 5-hydroxymethylcytosine-based liquid biopsy assays for early cancer detection (now part of Genentech/Roche). Comparable as an emerging methylation/epigenetic-based cancer detection company with a similar technology-to-product trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syndex Bio